摘要
Abstract
Objective:To analyze the effects of Xiaoaijiedu prescription plus immune checkpoint inhibitor on advanced lung adenocarcinoma patients with negative driver genes.Method:A total of 84 patients with advanced lung adenocarcinoma with driver gene negative from October 2021 to October 2023 were selected as the study objects and divided into a control group and an observation group by random number table method,with 42 cases in each group.The control group was treated with immune checkpoint inhibitor,while the observation group was treated with Xiaoaijiedu prescription on the basis of the control group.The course of treatment lasted until the end of chemotherapy.Traditional Chinese medicine symptom score,lung function,cancer-related fatigue degree and quality of life before and after treatment were compared between the two groups.Result:After treatment,the scores of TCM symptoms in the observation group were lower than control group after treatment,and the differences were statistically significant(P<0.05).The levels of respiratory function indexes in the observation group were higher than control group,and the differences were statistically significant(P<0.05).The cancer fatigue score in observation group was lower than control group,and the quality of life score was higher than control group,and the differences were statistically significant(P<0.05).The objective remission rate and disease control rate of observation group were higher than control group,and the differences were not statistically significant(P>0.05).Conclusion:In patients with advanced lung adenocarcinoma with negative driver genes,enhanced treatment with Xiaoaijiedu prescription on the basis of immune checkpoint inhibitors can obtain exact curative effect,which can significantly improve clinical symptoms and lung function,reduce cancerous fatigue,and improve life quality.关键词
驱动基因阴性晚期肺腺癌/免疫检查点抑制剂/消癌解毒方/肺功能/癌因性疲乏/生存质量Key words
Driver gene negative advanced lung adenocarcinoma/Immune checkpoint inhibitors/Xiaoaijiedu prescription/Lung function/Cancer-related fatigue/Quality of life
